Decomplexation proteomic analysis and purity assessment of a biologic for snakebite envenoming: Philippine Cobra Antivenom
Transactions of The Royal Society of Tropical Medicine and Hygiene · 2023
DOI: 10.1093/trstmh/trac125 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transactions of The Royal Society of Tropical Medicine and Hygiene, 2023. Verfasst von Praneetha Palasuberniam und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, University Malaysia Sabah, 88400 Kota Kinabalu, Sabah, Malaysia. Hauptthemen laut MEDLINE: Antivenins, Snake Bites. Die Arbeit nennt 45 Literaturangaben. Gefördert von: Ministry of Higher Education, Government of Malaysia.
Abstract (Originalsprache)
Background
Philippine Cobra Antivenom (PCAV) is the only snake antivenom manufactured in the Philippines. It is used clinically to treat envenoming caused by the Philippine Spitting Cobra (Naja philippinensis). While PCAV is effective pharmacologically, it is crucial to ensure the safety profile of this biologic that is derived from animal plasma.
Methods
This study examined the composition purity of PCAV through a decomplexation proteomic approach, applying size-exclusion chromatography (SEC), sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and tandem mass spectrometry liquid chromatography-tandem mass spectrometry (LC-MS/MS).
Results
SDS-PAGE and SEC showed that the major protein in PCAV (constituting ∼80% of total proteins) is approximately 110 kDa, consistent with the F(ab’)2 molecule. This protein is reducible into two subunits suggestive of the light and heavy chains of immunoglobulin G. LC-MS/MS further identified the proteins as equine immunoglobulins, representing the key therapeutic ingredient of this biologic product. However, protein impurities, including fibrinogens, alpha-2-macroglobulins, albumin, transferrin, fibronectin and plasminogen, were detected at ∼20% of the total antivenom proteins, unveiling a concern for hypersensitivity reactions.
Conclusions
Together, the findings show that PCAV contains a favorable content of F(ab’)2 for neutralization, while the antibody purification process awaits improvement to minimize the presence of protein impurities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, University Malaysia Sabah, 88400 Kota Kinabalu, Sabah, Malaysia.
- Venom Research & Toxicology Laboratory, Department of Pharmacology, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia.
- Protein and Interactomics Laboratory, Department of Molecular Medicine, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia.
- Department of Emergency Medicine, Ospital ng Muntinlupa, 1781 Muntinlupa, Manila, Philippines.
- Department of Internal Medicine, Davao Medical School Foundation Hospital, 8000 Davao City, Philippines.
ORCID-Profile: Choo Hock Tan
Förderung
- Ministry of Higher Education, Government of Malaysia
Zitieren
APA
Palasuberniam, P., Tan, K. Y., Chan, Y. W., Blanco, F. B., & Tan, C. H. (2023). Decomplexation proteomic analysis and purity assessment of a biologic for snakebite envenoming: Philippine Cobra Antivenom. Transactions of The Royal Society of Tropical Medicine and Hygiene. https://doi.org/10.1093/trstmh/trac125
Vancouver
Palasuberniam P, Tan KY, Chan YW, Blanco FB, Tan CH. Decomplexation proteomic analysis and purity assessment of a biologic for snakebite envenoming: Philippine Cobra Antivenom. Transactions of The Royal Society of Tropical Medicine and Hygiene. 2023. doi:10.1093/trstmh/trac125
BibTeX
@article{Palasuberniam2023,
author = {Palasuberniam, Praneetha and Tan, Kae Yi and Chan, Yi Wei and Blanco, Francis Bonn and Tan, Choo Hock},
title = {Decomplexation proteomic analysis and purity assessment of a biologic for snakebite envenoming: Philippine Cobra Antivenom},
journal = {Transactions of The Royal Society of Tropical Medicine and Hygiene},
year = {2023},
doi = {10.1093/trstmh/trac125}
}
EUVIMED